PulseSight Therapeutics
PrivateLast Round
Series A
Feb 13, 2025
Total Funding Raised
$54.14M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
PulseSight Therapeutics operates in Healthcare & Life Sciences and is based in Paris. Its latest recorded funding round was a Seed round in February 2024.
PulseSight Therapeutics is a biotechnology company that develops non-viral gene therapies for the treatment of retinal diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Medical Devices
Business Model
B2B
Customer Profile
Hardware Sales, Revenue Share, Government Contracts
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
PulseSight Therapeutics Comparables
Compare PulseSight Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Complement Therapeutics GmbH | 85% | |
| SparingVision | 76% | |
| Coave Therapeutics | 76% |
For institutional investors. Book with your work email.
PulseSight Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series A | Feb 13, 2025 | ||||
| Seed | Feb 28, 2024 | ||||
| Series B Extension | Aug 4, 2021 | ||||
| Series B | Jan 8, 2020 | ||||
| Series A | Sep 16, 2016 | ||||
VC Round | Apr 11, 2013 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
PulseSight Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Korea Investment Partners | Seed, Series B Extension |
| Inserm Transfert | Series A, Seed, Series B, VC Round |
| Pontifax Venture Capital | Series A, Series B |
| +ND Capital | Seed |
| Pureos Bioventures | Series A, Series B, Seed |
| Boehringer Ingelheim Venture Fund | Series A, VC Round, Series B |
| Karista | Series A, Seed, Series B, VC Round |
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 21, 2026
Monthly visitors increased 33% MoM.
- Jul 26, 2026
Monthly visitors increased 43% MoM.
For institutional investors. Book with your work email.
PulseSight Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about PulseSight Therapeutics's valuation, stock price, and market status.
Is PulseSight Therapeutics a public or private company?
PulseSight Therapeutics is a private company.
What is the current stock price of PulseSight Therapeutics?
PulseSight Therapeutics is a private company, so its shares have no public market price. Caplight tracks PulseSight Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is PulseSight Therapeutics worth (valuation)?
Valuation information for PulseSight Therapeutics is not publicly available.
Can I buy PulseSight Therapeutics stock?
PulseSight Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was PulseSight Therapeutics's last funding round?
PulseSight Therapeutics's most recent funding round was Series A on February 13, 2025.
Who are the main investors in PulseSight Therapeutics?
Key investors in PulseSight Therapeutics include Korea Investment Partners, +ND Capital, Pureos Bioventures, Boehringer Ingelheim Venture Fund.
Will PulseSight Therapeutics IPO soon?
No public IPO plans have been announced for PulseSight Therapeutics.
How can I track PulseSight Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in PulseSight Therapeutics's shares on secondary markets.